Hardman & Co Research
Hardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in
Europe
28-Jan-2020 / 12:15 GMT/BST
Hardman & Co Research: Good demand for Feraccru in Europe
Shield Therapeutics (STX) is a commercial-stage company delivering specialty
products that address patients' unmet medical needs, with an initial focus on
treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had
approved this drug for a broad indication opened up a market in the US
currently worth over $1bn p.a. - a US partnership deal is expected in 2020. A
2019 trading update showed STX's performance to be in line with expectations,
with GBP0.6m in sales-related revenue from Norgine's sales of Feraccru in Europe
and GBP2.3m in milestones. STX's cash runway extends into 2021, in the absence
of a US deal.
Please click on the link below for the full report:
https://www.hardmanandco.com/research/corporate-research/good-demand-for-ferac
cru-in-europe/ [1]
If you are interested in meeting the company, you can register your interest
by clicking on the above link
To contact us: Contact:
Hardman & Co Martin Hall mh@hardmanandco.com
35 New Broad Street
London +44 20 7194 7632
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter
@HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [2] to read the statement.
About Hardman & Co: For the past 25 years Hardman has been producing
specialist research designed to improve investors' understanding of companies,
sectors, industries and investment securities. Our analysts are highly
experienced in their sectors, and have often been highly rated by professional
investors for their knowledge. Our focus is to raise companies' profiles
across the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been commissioned by
the company which is the subject of the note; this is clearly stated in the
disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative
of Capital Markets Strategy Ltd and is authorised and regulated by the
Financial Conduct Authority; our FCA registration number is 600843. Hardman
Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community,
market counterparties and sophisticated and high net worth investors as
defined in the rules of the regulatory bodies. It is not intended to be made
available to unsophisticated retail investors. Anyone who is unsure of their
categorisation should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security. Please read
the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
962357 28-Jan-2020
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a1213b01e4f1cb1ee6eb1ebbe787257&application_id=962357&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=962357&site_id=vwd&application_name=news
(END) Dow Jones Newswires
January 28, 2020 07:15 ET (12:15 GMT)
© 2020 Dow Jones News
